CANNABINOID RECEPTOR REFERENCES



2002 REFERENCES

Noah L. 2002
Attorney General's intrusion into clinical practice.
N Engl J Med. 2002 Jun 13;346(24):1918-9; discussion 1918-9.
PMID: 12066817 [PubMed - indexed for MEDLINE]

MacDonald R. 2002,
Attorney General's intrusion into clinical practice.
N Engl J Med. 2002 Jun 13;346(24):1918-9; discussion 1918-9. 
PMID: 12063384 [PubMed - indexed for MEDLINE]

Lowenstein E, Wanzer SH. 2002
The U.S. Attorney General's intrusion into medical practice.
N Engl J Med. 2002 Feb 7;346(6):447-8. 
PMID: 11832536 [PubMed - indexed for MEDLINE]
(Note: Our Founding Fathers warned about the government 
intruding into our medical conditions, records and treatments! 
This slippery slope has gotten a lot steeper and more precipitous.
Are not our Medical Rights as important as any other Human Right?)

These are some other new (2002) references, more coming soon.

Carter GT, Weydt P. 2002
Cannabis: old medicine with new promise for neurological disorders.
Curr Opin Investig Drugs. 2002 Mar;3(3):437-40.
PMID: 12054093 [PubMed - in process]

Mechoulam R. 2002,  (over 30 years of publications !)
Discovery of endocannabinoids and some random thoughts
on their possible roles in neuroprotection and aggression.
Prostaglandins Leukot Essent Fatty Acids. 2002 Feb;66(2-3):93-9.
PMID: 12052029 [PubMed - in process]
(Note:  This is published in this journal because Anandamide is
Endogenous Essential Fatty Acid that fits CB1 & CB2? receptors,
and Postagladins are related chemical group with end closed into ring.
The connection between Postagladins in cell membrane and pain etc. and 
anandamide and THC agonists at receptors is still not fully known
but could have important relationships)

Lutz B. 2002 
Molecular biology of cannabinoid receptors.
Prostaglandins Leukot Essent Fatty Acids. 2002 Feb;66(2-3):123-42.
PMID: 12052031 [PubMed - in process]

Pertwee RG, Ross RA. 2002 
Cannabinoid receptors and their ligands.
Prostaglandins Leukot Essent Fatty Acids. 2002 Feb;66(2-3):101-21.
PMID: 12052030 [PubMed - in process]

Williams CM, Kirkham TC. 2002 
Observational analysis of feeding induced by Delta(9)-THC and anandamide.
Physiol Behav. 2002 Jun;76(2):241-50.
PMID: 12044596 [PubMed - in process]


Manara L, Croci T, Guagnini F, Rinaldi-Carmona M, 
Maffrand JP, Le Fur G, Mukenge S, Ferla G. 2002
Functional assessment of neuronal cannabinoid receptors 
in the muscular layers of human ileum and colon.
Dig Liver Dis. 2002 Apr;34(4):262-9.
PMID: 12038810 [PubMed - in process]

Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, 
Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. 2002
Int. Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors.
Pharmacol Rev. 2002 Jun;54(2):161-202.
PMID: 12037135 [PubMed - in process]

Conboy JR. 2002
Smoke screen: America's drug policy and medical marijuana.
Food Drug Law J. 2000;55(4):601-17. 
PMID: 12025852 [PubMed - indexed for MEDLINE]

Martin BR. 2002
Identification of the endogenous cannabinoid system 
through integrative pharmacological approaches.
J Pharmacol Exp Ther. 2002 Jun;301(3):790-6. Review.
PMID: 12023505 [PubMed - indexed for MEDLINE]

Onaivi ES, Leonard CM, Ishiguro H, Zhang PW, Lin Z, Akinshola BE, Uhl GR. 2002
Endocannabinoids and cannabinoid receptor genetics.
Prog Neurobiol. 2002 Apr;66(5):307-44.
PMID: 12015198 [PubMed - in process]

Moffat AC. 2002
The legalization of Cannabis for medical use.
Sci Justice. 2002 Jan-Mar;42(1):55-7. No abstract available.
PMID: 12012651 [PubMed - indexed for MEDLINE]

Killestein J, Hoogervorst EL, Reif M, Kalkers NF, 
Van Loenen AC, Staats PG, Gorter RW, Uitdehaag BM, Polman CH. 2002
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Neurology. 2002 May 14;58(9):1404-7.
PMID: 12011290 [PubMed - indexed for MEDLINE]

Thompson AJ, Baker D. 2002
Cannabinoids in MS: potentially useful but not just yet!
Neurology. 2002 May 14;58(9):1323-4. No abstract available.
PMID: 12011274 [PubMed - indexed for MEDLINE]

O'Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, 
Andreasen NC, Ponto LB, Watkins GL, Hurtig RR, Hichwa RD. 2002 
Effects of smoking marijuana on brain perfusion and cognition.
Neuropsychopharmacology. 2002 Jun;26(6):802-16.
PMID: 12007751 [PubMed - in process] 

Degenhardt L, Hall W. 2002 
Cannabis and psychosis.
Curr Psychiatry Rep. 2002 Jun;4(3):191-6.
PMID: 12003681 [PubMed - in process]

Maccarrone M, Bari M, Battista N, Di Rienzo M, Finazzi-Agro A. 2002 
Endogenous cannabinoids in neuronal and immune cells: 
toxic effects, levels and degradation.
Funct Neurol. 2001;16 Suppl 4:53-60. Review. No abstract available.
PMID: 12002040 [PubMed - indexed for MEDLINE]

Gruber AJ, Pope HG Jr. 2002 
Marijuana use among adolescents. 
Pediatr Clin North Am. 2002 Apr;49(2):389-413. Review. 
PMID: 11993290 [PubMed - indexed for MEDLINE]

Maldonado R, Rodriguez de Fonseca F. 2002 
Cannabinoid addiction: behavioral models and neural correlates. 
J Neurosci. 2002 May 1;22(9):3326-31. Review. 
PMID: 11978807 [PubMed - indexed for MEDLINE] 

Wilson RI, Nicoll RA. 2002 
Endocannabinoid signaling in the brain. 
Science. 2002 Apr 26;296(5568):678-82. Review. 
PMID: 11976437 [PubMed - indexed for MEDLINE]

Parker LA, Mechoulam R, Schlievert C. 2002 
Cannabidiol, a non-psychoactive component 
of cannabis and its synthetic dimethylheptyl
homolog suppress nausea in an experimental model with rats.
Neuroreport. 2002 Apr 16;13(5):567-70.
PMID: 11973447 [PubMed - in process]

Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT. 2002 
CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain.
Pain. 2002 Apr;96(3):253-60. No abstract available.
PMID: 11972997 [PubMed - in process]

Mechoulam R, Spatz M, Shohami E. 2002 
Endocannabinoids and neuroprotection.
Sci STKE. 2002 Apr 23;2002(129):RE5. Review.
PMID: 11972360 [PubMed - indexed for MEDLINE]

Elphick MR. 2002 
Evolution of Cannabinoid Receptors in Vertebrates: 
Identification of a CB(2) Gene in the Puffer Fish Fugu rubripes.
Biol Bull. 2002 Apr;202(2):104-7. No abstract available.
PMID: 11971807 [PubMed - in process]

Niveau G. 2002 
Cannabis-related flash-back, a medico-legal case
Encephale. 2002 Jan-Feb;28(1):77-9. French.
PMID: 11963347 [PubMed - indexed for MEDLINE]

Devlin MG, Christopoulos A. 2002 
Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum.
J Neurochem. 2002 Mar;80(6):1095-102.
PMID: 11953460 [PubMed - indexed for MEDLINE]

Vanhoenacker G, Van RP, De KD, Sandra P. 2002 
Chemotaxonomic features associated with flavonoids of cannabinoid-free cannabis 
(Cannabis sativa subsp. sativa L.) in relation to hops (Humulus lupulus L.).
Nat Prod Lett. 2002 Feb;16(1):57-63.
PMID: 11942684 [PubMed - indexed for MEDLINE]

Brune K. 2002 
Next generation of everyday analgesics.
Am J Ther. 2002 May-Jun;9(3):215-23. Review.
PMID: 11941381 [PubMed - indexed for MEDLINE]

Sil'kis IG. 2002 
Possible mechanism of cannabinoid-mediated modulation 
of signal transduction through the basal ganglia.
Ross Fiziol Zh Im I M Sechenova. 2002 Feb;88(2):144-57. Review. Russian.
PMID: 11938644 [PubMed - indexed for MEDLINE]

Lane SD, Cherek DR. 2002 
Marijuana effects on sensitivity to reinforcement in humans.
Neuropsychopharmacology. 2002 Apr;26(4):520-9.
PMID: 11927176 [PubMed - indexed for MEDLINE]

Storr M, Gaffal E, Saur D, Schusdziarra V, Allescher HD. 2002 
Effect of cannabinoids on neural transmission in rat gastric fundus.
Can J Physiol Pharmacol. 2002 Jan;80(1):67-76.
PMID: 11911227 [PubMed - in process]

Marsicano G, Moosmann B, Hermann H, Lutz B, Behlt C. 2002 
Neuroprotective properties of cannabinoids against oxidative stress: 
role of the cannabinoid receptor CB1.
J Neurochem. 2002 Feb;80(3):448-56.
PMID: 11905991 [PubMed - indexed for MEDLINE]

Zagnoni PG, Albano C. 2002 
Psychostimulants and epilepsy.
Epilepsia. 2002;43 Suppl 2:28-31.
PMID: 11903480 [PubMed - indexed for MEDLINE]


Schapiro RT. 2002 
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Curr Neurol Neurosci Rep. 2001 May;1(3):299-302. Review.
PMID: 11898533 [PubMed - indexed for MEDLINE]

Singer HS. 2002 
The treatment of tics.
Curr Neurol Neurosci Rep. 2001 Mar;1(2):195-202. Review.
PMID: 11898516 [PubMed - indexed for MEDLINE]

Molina-Holgado F, Molina-Holgado E, Guaza C, Rothwell NJ. 2002 
Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on
lipopolysaccharide-induced nitric oxide release in astrocyte cultures.
J Neurosci Res. 2002 Mar 15;67(6):829-36.
PMID: 11891798 [PubMed - indexed for MEDLINE]

Wenger T, Gerendai I, Fezza F, Gonzalez S, Bisogno T, Fernandez-Ruiz J, Di Marzo V.
The hypothalamic levels of the endocannabinoid, anandamide, 
peak immediately before the onset of puberty in female rats.
Life Sci. 2002 Feb 8;70(12):1407-14.
PMID: 11883716 [PubMed - indexed for MEDLINE]

Cloud J. 2002 
This bud's not for you.
Time. 2002 Feb 18;159(7):60-1. No abstract available.
PMID: 11881440 [PubMed - indexed for MEDLINE]

Yoshida T, Hashimoto K, Zimmer A, Maejima T, Araishi K, Kano M. 2002 
The cannabinoid CB1 receptor mediates retrograde signals for 
depolarization-induced suppression of inhibition in cerebellar Purkinje cells.
J Neurosci. 2002 Mar 1;22(5):1690-7.
PMID: 11880498 [PubMed - indexed for MEDLINE]

Buchwald A, Derendorf H, Ji F, Nagaraja NY, Wu WM, Bodor N. 2002 
Soft cannabinoid analogues as potential anti-glaucoma agents.
Pharmazie. 2002 Feb;57(2):108-14.
PMID: 11878185 [PubMed - indexed for MEDLINE]

Ford WR, Honan SA, White R, Hiley CR. 2002 
Evidence of a novel site mediating anandamide-induced negative 
inotropic and coronary vasodilatator responses in rat isolated hearts.
Br J Pharmacol. 2002 Mar;135(5):1191-8.
PMID: 11877326 [PubMed - in process]



2001 REFERENCES Klein TW, Newton CA, Friedman H. 2001 Cannabinoids and the immune system. Pain Res Manag. 2001 Summer;6(2):95-101. Review. PMID: 11854771 [PubMed - indexed for MEDLINE] LA CBC Medical Marijuana References
    PART 1 Cannabinoid Revolution R. Mechoulam, EA Carlin, 1978 Towards Drugs Derived from Cannabis, Naturewissenshaften 65:4, 174-9, April 1978 AC Howlett, RM Fleming, 1984 Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma membranes, Molecular Pharmacology, 23:6, 532-8, November 1984 AC Howlett, MR Johnson, GM Milne, 1988 Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model, Molecular Pharmacology, 33:3, 297-302, March 1988 M Bidaut-Russel, WA Devane, AC Howlett, 1990 Cannabinoid receptors and modulation of cyclic AMP accumulation in the brain, Journal of Neurochemistry, 55:1, 21-6, July 1990 LA Matsuda, SJ Lolait, MJ Brownstein, AC Young, TI Bonner, 1990 Structure of a cannabinoid receptor and functional expression of the cloned cDNA, Nature, 346:6284, 561-4, August 9, 1990 M Herkenham, AB Little, MR Johnson, LS Melvin, BR de Costa, KC Rice, 1990 Cannabinoid receptor localization in the brain, Proceedings of the National Academy of Science, 87:5, 1932-6, March 1990 WA Devane, L Hanaus, A Breuer, RG Pertwee, LA Stevenson, G Griffin, D GIbson, A Mandelbaum, A Etinger, R Mechoulam, 1992 Isolation and structure of a brain constituent that binds to the cannabinoid receptor, Science, 258:5090, 1946-9, December 18, 1992 S Munro, KL Thomas, M Abu-Shaar, 1993 Molecular characterization of a peripheral receptor for cannabinoids, Nature, 365:6441, 61-5, September 2, 1993 M Rinaldi-Carmona, F Barth, M Heaulme, D Shire, B Calandra, C Congy, S Martinez, J Maruani, G Naeliat, D Caput, et al, 1994 SR141716A, a potent and selective antagonist of the brain cannabinoid receptor, FEBS Lett, 350:2-3, 240-4, August 22, 1994 AC Howlett, 1995 Pharmacology of the cannabinoid receptor, Annual Review of Pharmacology and Toxicology, 1995 PART 2 Cannabinoids and the Brain M Herkenham, AB Little, MR Johnson, LS Melvin, BR de Costa, KC Rice, 1990 Cannabinoid receptor localization in the brain, Proc. National Academy of Science, 87:5, 1932-6, March 1990 TM Westlake, AC Howlett, SF Ali, MG Paule, AC Scallet, W Slikker Jr, 1991 Chronic exposure to delta-9-tetrahydrocannabinol fails to irreversibly alter brain cannabinoid receptors, Brain Research, 544:1, 145-9, March, 1991 M Rinaldi-Carmona, F Barth, M Heaulme, D Shire, B Calandra, C Congy, S Martinez, J Maruani, G Naeliat, D Caput, et al, 1994 SR141716A, a potent and selective antagonist of the brain cannabinoid receptor, FEBS Lett, 350:2-3, 240-4, August 1994 JP Teranova, JJ Storme, N Lafon, A Paeario, M Rinaldi-Carmona, G Le Fur, P Soubriae, 1996 Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist SR141716, Psychopharmacology (Berl), 126:2, 165-72, July 1996 V Santucci, P Soubriae, G Le Fur, 1996 Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR141716A in rats as assessed by the electroencephalographic spectral and sleep-waking and sleep-waking cycle analysis, Life Science, 58:6, PL103-10, 1996 TM Westlake, AC Howlett, TI Bonner, LA Matsuda, M Herkenham, 1994 Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybrization histochemistry of normal aged and Alzheimer's brains, Neuroscience, 63:3, 637-52, December 1994 RC Belue, AC Howlett, TM Westlake, DE Hutchings, 1995 The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats, Neurotoxicology and Teratology, 17:1, 25-30, January-February 1995 E Fride, R Mechoulam, 1996 Ontogenetic development of the response to anandamide and delta 9-tetrahydrocannabinol in mice, Brain Res Dev Brain Res, 95:1, 131-4, August 1996 K Varga, K Lake, BR Martin, G Kunos, 1995 Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide, European Journal of Pharmacology, 278, 279-283, 1995 EF Ellis, SF Moore, KA Willoughby, 1995 Anandamide and delta-9 THC dilation of cerebral arterioles is blocked by indomethacin, American Journal of Physiology, 269:6 Pt 2, H1859-64, Dec 1995 MD Randall, SP Alexander, T Bennett, EA Boyd, JR Fry, SM Gardiner, PA Kemp, AI McCulloch, DA Kendall, 1996 An endogenous cannabinoid as an endothelium-derived vasorelaxant, Biochem Biophys Res Commun, 229:1, 114-20, Dec 1996 PART 3 Cannabinoids and the Immune System WD Lyman, JR Sonnett, CF Brosnan, MB Bornstein,1989 Delta 9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis, Journal of Neuroimmunology, 23:1, 73-81, June 1989 S Munro, KL Thomas, M Abu-Shaar, 1993 Molecular characterization of a peripheral receptor for cannabinoids, Nature, 365:6441, 61-5, September 2, 1993 AB Lynn, M Herkenham, 1994 Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids, J. Pharmacology and Experimental Therapeutics, 268:3, 1612-23, 1994 S Galiaegue, S Mary, J Marchand, D Dussossouy, D Carriaere, P Carayon, M Bouaboula, D Shire, G Le Fur, P Cassellas, 1995 Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations, European Journal of Biochemistry, 232:1, 54-61, August 1995 R Mechoulam, S Ben Shabat, L Hanaus, E Fride, Z Vogel, M Bayewich, AE Sulcova, 1996 Endogenous Ligands -- chemical and biological studies, Lipid Mediat Cell Signal, 14:1-3, 45-9, September 1996 KL McCoy, D Gainey, GA Cabral, 1995 Delta 9-tetrahydrocannabinol modulates antigen processing by macrophages, J. Pharmacology and Experimental Therapeutics, 273:1216-1223, 1995 M Bayewich, T Avidor-Reiss, R Levy, J Barg, R Mechoulam, Z Vogel, 1995 The peripheral cannabinoid receptor: adenylate cyclase inhibition and G Protein coupling, FEBS Lett, 375:1-2, 143-7, November 1995 M Bayewich, MH Rhee, T Avidor-Reiss, A Breuer, R Mechoulam, Z Vogel, 1996 (-)-Delta 9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylate cyclase, J Biol Chem, 271:17, 9902-5, April 1996 M Bouaboula, C Poinot-Chazel, X Canat, B Bourriae, M Rinaldi-Carmona, B Calandra, G Le Fur, P Cassellas, 1996 Signalling pathway associated with stimulation of CB2 peripheral cannabinoid receptor: Involvement of both mitogen-activated protein kinase and induction of Krox-24, European Journal of Biochemistry, 237:3, 704-11, May 1996 GB Stefano, Y Liu, MS Goligorsky, Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes, J Biol Chem, 271:32, 19238-42, August 1996 D Burnette-Curley, F Marciano-Cabral, K Fischer-Stenger, GA Cabral, 1993 delta 9-Tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmaette-Guaerin-activated macrophages, International Journal of Immunopharmacology, 15:3, 371-82, April 1993 D Burnette-Curley, GA Cabral, 1995 Differential inhibition of RAW264.7 macrophage tumoricidal activity by delta 9-tetrahydrocannabinol, Proc Soc Exp Biol Med, 210:1, 64-76, October 1995 MS Smith, Y Yamamoto, C Newton, H Friedman, T Klein, 1997 Psychoactive cannabinoids increase mortality and alter acute phase cytokine responses in mice sublethally infected with Legionella pneumophila, Proc Soc Exp Biol Med, 214:1, 69-75, January 1997 JJ James, 1997 Medical Marijuana: Unpublished Federal Study Found THC-Treated Rats Lived Longer, Had Less Cancer, AIDS Treatment News 263, January 1997 NTP Technical Report on the Toxicology and Carcinogenesis Studies of 1-Trans-Delta 9-Tetrahydrocannabinol (CAS No. 1972-08-3) in F344/N Rats and B6C3F1 Mice (Gavages Studies), NTP TR 446, NIH Publication No. 94-3362 of US Dept. of HHS, NTP Central Data Management (919) 541-3419 SD Skaper, A Buriani, R Dal Toso, L Petrelli, S Romanello, L Facci, A Leon, The ALIAmide palmitoethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule cells, Proc. National Academy of Sciences USA, 93:9, 399984-9, April 1996 S Mazzari, R Canella, L Petrelli, G Marcolongo, A Leon, 1996 N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cells, European Journal of Pharmacology, 300:3, 227-36, April 1996 E Yoles, M Belkin, M Schwartz, 1996 HU211, a novel nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy, Journal of Neurotrauma, 31:1, 49-57, January 1996 R Bass, D Engelhard, V Tremblovler, E Shohami, 1996 A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis, Journal of Infectious Diseases, 17:3, 735-8, March 1996

    Medical Analyses References, Ganja In Jamaica
    Receptors
    Abood & Martin (1996). 
    Molecular neurobiology of the cannabinoid receptor.
    Int. Rev. Neurobiology, vol 39(?), pp. 197-221.
    
    Breivogel et.al (1997). 
    Regional differences in cannabinoid receptor/G-protein coupling in rat brain. 
    J. Pharmacol. Exp. Ther. 282:1632-1642, 1997. 
    
    Di Marzo et.al (1998). 
    Interactions between synthetic vanilloids 
    and the endogenous cannabinoid system. 
    FEBS Letters 436 (1998) 449-454. 
    
    Facci et.al (1995) 
    Mast cells express a peripheral cannabinoid receptor with
    differemtial sensitivity to anandamine and palmitoylethanolamide. 
    Proc. Natl. Acad. Sci. Vol 92, pp. 3376-3380. April 1995, Pharmacology.
    
    Garcia et.al (1998) 
    Protein kinase C disrupts cannabinoid actions by
    phosphorylation of the CB1 cannabinoid receptor. 
    J. Neuroscience, April 15, 1998, 18(8):2834-2841.
    
    Gifford et.al (1999). 
    Large receptor reserve for cannabinoid 
    actions in the central nervous system. 
    J. Pharmacol. Exp. Ther. 288:478-483, 1999. 
    
    Glass & Felder (1997) 
    Concurrent stimulation of cannabinoid CB1 and dopamine D2 
    receptors augments cAMP accumulation in striatal neurons:
    evidence for a Gs linkage to the CB1 receptor. 
    J. Neuroscience, July 15, 1997, 17(14):5327-5333. 
    
    Howlett et al. (1990) 
    Classical and nonclassical cannabinoids: mechanisms
    of action-brain binding. 
    NIDA Res Monogr Ser 1990;96:100-110.
    
    Howlett et.al (1998) 
    Characterization of CB1 cannabinoid receptors using
    receptor peptide fragments and site-directed antibodies. 
    Mol. Pharmacology 53:504-510 (1998).
    
    Howlett et.al (1988). 
    Nonclassical cannabinoid analgetics inhibit adenylate cyclase: 
    development of a cannabinoid receptor model. 
    Mol. Pharmacology, 33: 297-302.
    
    Matsuda et.al (1990) 
    Structure of a cannabinoid receptor and 
    functional expression of the cloned cDNA. 
    Nature, Vol 346, 9 August 1990.
    
    Romero et.al (1997). 
    Atypical location of cannabinoid receptors in white
    matter areas during rat brain development. 
    Synapse 26:317-323 (1997). 
    
    Romero et.al (1998) 
    Time-course of the cannabinoid receptor down-regulation 
    in the adult rat brain caused by repeated exposure to
    delta9-tetrahydrocannabinol. 
    Synapse 30: 298-308 (1998). 
    
    Shire et.al (1996) 
    Structural features of the central cannabinoid CB1receptor 
    involved in the binding of the specific CB1 antagonist SR141716A.
    J. Biol. Chemistry, Vol 271, No 12, March 22, 1996, pp. 6941-6946. 
    
    Sim et.al (1996) 
    Effects of chronic treatment with delta9-tetrahydrocannabinol 
    on cannabinoid-stimulated [35S]GTPgamaS autoradiography in rat brain. 
    J. Neuroscience, December 15, 1996, 16(24):8057-8066.
    
    Tao & Abood (1998) 
    Mutation of a highly conserved aspartate residue in the
    second transmembrane domain of the cannabinoid receptors, 
    CB1 and CB2, disrupts G-protein coupling. 
    J. Pharmacol. Exp. Ther. 285:651-658, 1998. 
    
    Reviews
    
    Felder & Glass (1998) 
    Cannabinoid receptors and their endogenous agonists. 
    Ann. Rev. Pharmacol. Toxicol. 1998 38:179-200. 
    
    Glass et.al (1997) 
    Cannabinoid receptors in the human brain: 
    a detailed anatomical and quantitative autoradiographic 
    study in fetal neonatal and adult human brain. 
    Neuroscience, Vol 27, No 2, pp. 299-318.
    
    Hollister (1986) 
    Health aspects of cannabis. 
    Pharmacol. Reviews Vol. 38, No. 1, 1986.
    
    Hollister (1988) Cannabis. 
    Acta Psychiatr. Rev. Suppl. 345, 1988:78-108.
    
    Howlett (1995) 
    Pharmacology of cannabinoids receptors. 
    Annu. Rev. Pharmacol. Toxicol. 1995 35:607-634.
    

    3 More Refs Houston, D.B., Howlett, A.C. Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. Mol. Pharmacol. 43: 17-22 (1993). Thomas, B.F., Wei, X., and Martin, B.R. Characterization and autoradiographic localization of the cannabinoid binding site in rat brain using [3H]11-OH-D9-THC-DMH. J. Pharmacol. Exp. Ther. 263: 1383-1390 (1992). Jarbe TU, Hiltunen AJ, Mathis DA, Hanus L, Bruer A, Mechoulam R. Discriminative stimulus effects and receptor binding of enantiomeric pairs of cannabinoids in rats and pigeons; a comparison. J. Pharmacol. Exp. Ther. 264: 561-569 1993.

    Dawn Lyons-Johnson, ARS Information Staff, Greenbelt MD Gary D. Weesner Cannabinoid Receptors Key to Stress Response USDA-ARS Livestock Behavior Research Unit, Purdue University,

    IOM 1999 Chap 2 References Abood ME, Martin BR. 1996. Molecular neurobiology of the cannabinoid receptor. International Review of Neurobiology 39:197—221. Abood ME, Sauss C, Fan F, Tilton CL, Martin BR. 1993. Development of behavioral tolerance to delta 9-THC without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacology, Biochemistry and Behavior 46:575—579. Aceto MD, Scates SM, Lowe JA, Martin BR. 1995. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. European Journal of Pharmacology 282:R1—R2. Adams IB, Martin BR. 1996. Cannabis: Pharmacology and toxicology in animals and humans. Addiction 91:1585—1614. Baczynsky WO, Zimmerman AM. 1983a. Effects of delta-9-tetrahydrocannabinol, cannabinol, and cannabidiol on the immune system in mice: I. In vivo investigation of the primary and secondary immune response. Pharmocology 26:1—11. Baczynsky WO, Zimmerman AM. 1983b. Effects of delta 9-tetrahydrocannabinol, cannabinol and cannabidiol on the immune system in mice. II. In vitro investigation using cultured mouse splenocytes. Pharmacology 26:12—19. Bass R, Engelhard D, Trembovler V, Shohami E. 1996. A novel nonpsychotropic cannabinoid, HU-211, in the treatment of experimental pneumococcal meningitis. Journal of Infectious Diseases 173:735—738. Beardsley PM, Balster RL, Harris LS. 1986. Dependence on tetrahydrocannabinol in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 239:311—319. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, DiMarzo V, Mechoulam R. 1998. An entourage effect: Inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology 353:23—31. Bennett GJ. 1994. Neuropathic pain. In: Wall PD, Melzack R, Editors, Textbook of Pain. Edinburgh: Churchill Livingstone. Bird KD, Boleyn T, Chesher GB, Jackson DM, Starmer GA, Teo RKC. 1980. Inter-cannabinoid and cannabinoid-ethanol interactions and their effects on human performance. Psychopharmacology 71:181—188. Bloom AS, Dewey WL, Harris LS, Brosius KK. 1977. 9-nor-9b-hydroxyhexa-hydrocannabinol, a cannabinoid with potent antinociceptive activity: Comparisons with morphine. J. Pharmacology and Experimental Therapeutics 200:263—270. Bornheim LM, Everhart ET, Li J, Correia MA. 1994. Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochemical Pharmacology (England) 48:161—171. Bornheim LM, Kim KY, Chen B, Correia MA. 1993. The effect of cannabidiol on mouse hepatic microsomal cytochrome P450-dependent anandamide metabolism. Biochemical and Biophysical Research Communications (USA) 197:740—746. Bornheim LM, Kim KY, Li J, Perotti BY, Benet LZ. 1995. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metabolism and Disposition (USA) 23:825—831. Breivogel CS, Sim LJ, Childers SR. 1997. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J. of Pharmacology and Experimental Therapeutics 282:1632—1642. British Medical Association. 1997. Therapeutic Uses of Cannabis. Amsterdam, Netherlands: Harwood Academic Publishers. Burkey TH, Quock RM, Consroe P, Roeske WR, Yamamura HI. 1997. Delta-9-tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain. European Journal of Pharmacology 323:R3—R4. Buxbaum DM. 1972. Analgesic activity of 9-tetrahydrocannabinol in the rat and mouse. Psychopharmacology 25:275—280. Cabral GA , Dove Pettit DA. 1998. Drugs and immunity: Cannabinoids and their role in decreased resistance to infectious disease. Journal of Neuroimmunology 83:116—123. Cabral GA, Lockmuller JC, Mishkin EM. 1986. Delta-9-tetrahydrocannabinol decreases alpha/beta interferon response to herpes simplex virus type 2 in the B6C3F1 mouse. Proc. Society for Experimental Biology and Medicine 181:305—311. Calignano A, La Rana G, Giuffrida A, Piomelli D. 1998. Control of pain initiation by endogenous cannabinoids. Nature 394:277—281. Campbell KA, Foster TC, Hampson RE, Deadwyler SA. 1986a. Delta-9-tetrahydrocannabinol differentially affects sensory-evoked potentials in the rat dentate gyrus. J. Pharmacology and Experimental Therapeutics 239:936—940. Campbell KA, Foster TC, Hapson RE, Deadwyler SA. 1986b. Effects of delta-9-tetrahydrocannabinol on sensory-evoked discharges of granule cells in the dentate gyrus of behaving rats. J. Pharmacology and Experimental Therapeutics 239:941—945. Chen J, Marmur R, Pulles A, Paredes W, Gardner EL. 1993. Ventral tegmental microinjection of delta-9-tetrahydrocannabinol enhances ventral tegmental somatodendritic dopamine levels but not forebrain dopamine levels: Evidence for local neural action by marijuana's psychoactive ingredient. Brain Research 621:65—70. Childers SR. 1997. Opioid receptors: Pinning down the opiate targets. Current Biology 7:R695—R697. Childers SR, Breivogel CS. 1998. Cannabis and endogenous cannabinoid systems. Drug and Alcohol Dependence 51:173—187. Coffey RG, Yamamoto Y, Shella E, Pross S. 1996. Tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochemical Pharmacology 52:743—751. Collins DR, Pertwee RG, Davies SN. 1994. The action of synthetic cannabinoids on the induction of long-term potentiation in the rat hippocampal slice. European Journal of Pharmacology 259:R7—R8. Collins DR, Pertwee RG, Davies SN. 1995. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. British Journal of Pharmacology 115:869—870. Costa B, Parolaro D, Colleoni M. 1996. Chronic cannabinoid, CP-55,940, administration alters biotransformation in the rat. European Journal of Pharmacology 313:17—24. Daaka Y, Friedman H, Klein T. 1996. Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. J. Pharmacology and Experimental Therapeutics 276:776—783. Daaka Y, Zhu W, Friedman H, Klein T. 1997. Induction of interleukin-2 receptor gene by 9-tetrahydrocannabinol is mediated by nuclear factor B and CB1 cannabinoid receptor. DNA and Cell Biology 16:301—309. Deadwyler SA, Heyser CJ, Hampson RE. 1995. Complete adaptation to the memory disruptive effects of delta-9-THC following 35 days of exposure. Neuroscience Research Communications 17:9—18. Derocq JM, Segui M, Marchand J, Le Fur G, Casellas P. 1995. Cannabinoids enhance human B-cell growth at low nanomolar concentrations. FEBS Letters 369:177—182. Devane WA, Dysarc FA, Johnson MR, Melvin LS, Howlett AC. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology 34:605—613. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffing F, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946—1949. Dewey WL. 1986. Cannabinoid pharamacology. Pharmacology Review 38:151—178. Di Chiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. National Academy of Sciences, USA 85:5274—5278. Dill JA, Howlett AC. 1988. Regulation of adenylate cyclase by chronic exposure to cannabimimetic drugs. J. Pharmacology and Experimental Therapeutics 244:1157—1163. Evans DJ, Keith DEJ, Morrison H, Magendzo K, Edwards RH. 1992. Cloning of a delta opioid receptor by functional expression. Science 258:1952—1955. Fan F, Tao Q, Abood ME, Martin BR. 1996. Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Research 706:13—20. Felder CC, Glass M. 1998. Cannabinoid receptors and their endogenous agonists. Annual Reviews of Pharmacology and Toxicology 38:179—200. Felder CC, Nielsen A, Briley EM, Palkovits M, Priller J, Axelrod J, Nguyen DN, Richardson JM, Riggin RM, Koppel GA, Paul SM, Becker GW. 1996. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Letters 393:231—235. Fields HL. 1987. Pain. New York: McGraw-Hill. Formukong EA, Evans AT, Evans FJ. 1988. Analgesic and antiinflammatory activity of constituents of Cannabis sativa L. Inflammation 12:361—371. French ED. 1997. Delta-9-tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neuroscience Letters 226:159—162. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, Bouaboula M, Shire D, Le Fur G, Casellas P. 1995. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. European Journal of Biochemistry 232:54—61. Gessa GL, Mascia MS, Casu MA, Carta G. 1997. Inhibition of hippocampal acetylcholine release by cannabinoids: Reversal by SR 141716A. European Journal of Pharmacology 327:R1—R2. Gifford AN, Ashby Jr CR. 1996. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J. Pharmacology and Experimental Therapeutics 277:1431—1436. Gifford AN, Gardner EL, Ashby CRJ. 1997. The effect of intravenous administration of delta-9-tetrahydrocannabinol on the activity of A10 dopamine neurons recorded in vivo in anesthetized rats. Neuropsychobiology 36:96—99. Glass M, Dragunow M, Faull RLM. 1997. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77:299—318. Hadden JW, Hadden EM, Haddox MK, Goldberg ND. 1972. Guanosine 3΄:5΄-cyclic monophosphates: A possible intracellular mediator of mitogenic influences in lymphocytes. Proc. National Academy of Sciences, USA 69:3024—3027. Hampson AJ, Grimaldi M, Axelrod J, Wink D. 1998. Cannabidiol and (-)delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. National Academy of Sciences, USA 95:8268—8273. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. 1999. Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141:385—394. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. 1999. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 141:395—404. Herkenham M. 1995. Localization of cannabinoid receptors in brain and periphery. In: Pertwee RG, Editor, Cannabinoid Receptors. New York: Academic Press. Pp. 145—166. Herkenham M, Lynn AB, de Costa BR, Richfield EK. 1991a. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Research 547:267—274. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. 1991b. Characterization and localization of cannabinoid receptors in rat brain: A quantative in vitro autoradiographic study. Journal of Neuroscience 11:563—583. Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. 1990. Cannabinoid receptor localization in the brain. Proc. National Academy of Sciences, USA 87:1932—1936. Herring AC, Koh WS, Kaminski NE. 1998. Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappa B elements by cannabinol, a minimally CNS-active cannabinoid. Biochemical Pharmacology 55:1013—1023. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. 1997. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neuroscience Letters 221:157—160. Heyser CJ, Hampson RE, Deadwyler SA. 1993. Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: Alterations in short-term memory associated with changes in task-specific firing of hippocampal cells. J. Pharmacology and Experimental Therapeutics 264:294—307. Hohmann AG, Briley EM, Herkenham M. 1999. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Research 822:17—25. Hohmann AG, Herkenham M. 1998. Regulation of cannabinoid and mu opioid receptor binding sites following neonatal capsaicin treatment. Neuroscience Letters 252:13—16. Hohmann AG, Herkenham M. 1999. Localization of central cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat dorsal root ganglia: A double-label in situ hybridization study. Neuroscience 90:923—931. Hohmann AG, Martin WJ, Tsou K, Walker JM. 1995. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sciences 56:2111—2119. Hollister LE. 1986. Health aspects of cannabis. Pharmacological Reviews 38:1—20. Hollister LE, Gillespie BA. 1975. Interactions in man of delta-9-THC. II. Cannabinol and cannabidiol. Clinical Pharmacology and Therapeutics 18:80—83. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. 1975. Identification of two related pentapeptides from the brain with potent opiate agonists activity. Nature 258:577—580. Jackson AL, Murphy LL. 1997. Role of the hypothalamic-pituitary-adrenal axis in the suppression of luteinizing hormone release by delta-9-tetrahydrocannabinol. Neuroendocrinology 65:446—452. Jacob J, Ramabadran K, Campos-Medeiros M. 1981. A pharmacological analysis of levonantradol antinociception in mice. Journal of Clinical Pharmacology 21:327S—333S. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. 1998. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoyl-ethanolamide in visceral and somatic inflammatory pain. Pain 76:189—199. Jeon YJ, Yang K-H, Pulaski JT, Kaminski NE. 1996. Attenuation of inducible nitric oxide synthase gene expression by delta-9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-kB/Rel activation. Molecular Pharmacology 50:334—341. Johnson MR, Melvin LS. 1986. The discovery of non-classical cannabinoid analgesics. In: Mechoulam R, Editor, Cannabinoids as Therapeutic Agents. Boca Raton, FL: CRC Press, Inc. Pp. 121—145. Jones RT, Benowitz NL, Herning RI. 1981. Clinical relevance of cannabis tolerance and dependence. Journal of Clinical Pharmacology 21:143S—152S. Kaminski NE. 1996. Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Biochemical Pharmacology 52:1133—1140. Kaminski NE, Abood ME, Kessler FK, Martin BR, Schatz AR. 1992. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Molecular Pharmacology 42:736—742. Kaminski NE, Koh WS, Yang KH, Lee M, Kessler FK. 1994. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochemical Pharmacology 48:1899—1908. Kaminski NE. 1998. Regulation of cAMP cascade, gene expression and immune function by cannabinoid receptors. Journal of Neuroimmunology 83:124—132. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA. 1975. Cannabidiol interferes with the effects of delta-9-tetrahydrocannbinol in man. European Journal of Pharmacology 28:172—177. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. 1992. The delta-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc. National Academy of Sciences, USA 89:12048—12052. Kirby MT, Hampson RE, Deadwyler SA. 1995. Cannabinoids selectively decrease paired-pulse perforant path synaptic potentials in the dentate gyrus in vitro. Brain Research 688:114—120. Klein TW, Friedman H. 1990. Modulation of murine immune cell function by marijuana components. In: Watson R, Editor, Drugs of Abuse and Immune Function. Boca Raton, FL: CRC Press. Klein TW, Friedman H, Specter SC. 1998. Marijuana, immunity and infection. Journal of Neuroimmunology 83:102—115. Klein TW, Newton C, Friedman H. 1987. Inhibition of natural killer cell function by marijuana components. Journal of Toxicology and Environmental Health 20:321—332. Klein TW, Newton C, Friedman H. 1994. Resistance to Legionella pneumophila suppressed by the marijuana component, tetrahydrocannabinol. Journal of Infectious Diseases 169:1177—1179. Klein TW, Newton C, Friedman H. 1998. Cannabinoid receptors and immunity. Immunology Today 19:373—381. Klein TW, Newton C, Widen R, Friedman H. 1985. The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses. Journal of Immunopharmacology 7:451—466. Klein TW, Newton C, Widen R, Friedman H. 1993. Delta-9-tetrahydrocannabinol injection induces cytokine-mediated mortality of mice infected with Legionella pneumophila. J. Pharmacology and Experimental Therapeutics 267:635—640. Koh WS, Yang KH, Kaminski NE. 1995. Cyclic AMP is an essential factor in immune responses. Biochemical and Biophysical Research Communications 206:703—709. Ledent C , Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M. 1999. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401—404. Lee M, Yang KH, Kaminski NE. 1995. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. J. Pharmacology and Experimental Therapeutics 275:529—536. Lepore M, Liu X, Savage V, Matalon D, Gardner EL. 1996. Genetic differences in delta 9-tetrahydrocannabinol-induced facilitation of brain stimulation reward as measured by a rate-frequency curve-shift electrical brain stimulation paradigm in three different rat strains. Life Sciences 58:365—372. Lepore M, Vorel SR, Lowinson J, Gardner EL. 1995. Conditioned place preference induced by delta 9-tetrahydrocannabinol: Comparison with cocaine, morphine, and food reward. Life Sciences 56:2073—2080. Lichtman AH, Martin BR. 1991a. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacology and Experimental Therapeutics 258:517—523. Little PJ, Compton DR, Mechoulam R, Martin BR. 1989. Stereochemical effects of 11-OH-delta-8-THC-dimethylheptyl in mice and dogs. Pharmacology, Biochemistry Behavior 32:661—666. Lu F, Ou DW. 1989. Cocaine or delta-9-tetrahydrocannabinol does not affect cellular cytotoxicity in vitro. International Journal of Pharmacology 11:849—852. Luo YD, Patel MK, Wiederhold MD, Ou DW. 1992. Effects of cannabinoids and cocaine on the mitogen-induced transformations of lymphocytes of human and mouse origins. International Journal of Immunopharmacology 14:49—56. Lyman WD, Sonett JR, Brosnan CFER, Bornstein MB. 1989. Delta 9-tetrahydrocannabinol: A novel treatment for experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 23:73—81. Mailleux P, Vanderhaeghen JJ. 1992. Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 48:655—668. Martin WJ, Hohmann AG, Walker JM. 1996. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: Correlation between electrophysiological and antinociceptive effects. The Journal of Neuroscience 16:6601—6611. Martin WJ, Patrick SL, Coffin PO, Tsou K, Walker JM. 1995. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sciences 56:2103—2109. Martin WJ, Tsou K, Walker JM. 1998. Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjections into the rostral ventromedial medulla. Neuroscience Letters 242:33—36. Martoletta MC, Cossu G, Fattore L, Gessa GL, Fratta W. 1998. Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 85:327—330. Matsuda L, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346:561—564. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NSA, Gopher A, Almog S, Martin BR, Compton D, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z. 1995. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 50:83—90. Mechoulam R, Hanus L, Fride E. 1998. Towards cannabinoid drugs--revisited. In: Ellis GP, Luscombe DK, Oxford AW, Editors, Progress in Medicinal Chemistry. v. 35. Amsterdam: Elsevier Science. Pp. 199—243. Meng ID, Manning BH, Martin WJ, Fields HL. 1998. An analgesia circuit activated by cannabinoids. Nature 395:381—383. Matsuda LS, Bonner TI, Lolait SJ (1993) Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol 327:535­550. Miller AS, Walker JM. 1996. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. European Journal of Pharmacology 304:29—35. Munro S, Thomas KL, Abu-Shaar M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61—65. Murphy LL, Steger RW, Smith MS, Bartke A. 1990. Effects of delta-9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat. Neuroendocrinology 52:316—321. Narimatsu S, Watanabe K, Matsunaga T, Yamamoto I, Imaoka S, Funae Y, Yoshimura H. 1993. Suppression of liver microsomal drug-metabolizing enzyme activities in adult female rats pretreated with cannabidiol. Biological and Pharmaceutical Bulletin (Japan) 16:428—430. Nestler EJ, Aghajanian GK (1997) Molecular and cellular basis of addiction. Science 278:58­63. Newton CA, Klein T, Friedman H. 1994. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infection and Immunity 62:4015—4020. Norwicky AV, Teyler TJ, Vardaris RM. 1987. The modulation of long-term potentiation by delta-9-tetrahydrocannabinol in the rat hippocampus, in vitro. Brain Research Bulletin 19:663. O'Leary D, Block RI, Flaum M, Boles Ponto LL, Watkins GL, Hichwa RD. 1998. Acute marijuana effects on rCBF and cognition: A PET study. Abstracts--Society for Neuroscience, 28th Annual Meeting. Los Angeles, November 7—12, 1998. Washington, DC: Society for Neuroscience. Ohlsson A, Lindgren J-E, Wahlen A, Agurell S, Hollister LE, Gillespie HK. 1980. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clinical Pharmacology and Therapeutics 28:409—416. Oviedo A, Glowa J, Herkenham M. 1993. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A quantitative autoradiographic study. Brain Research 616:293—302. Pacheco MA, Ward SJ, Childers SR. 1993. Identification of cannabinoid receptors in cultures of rat cerebellar granule cells. Brain Research 603:102—110. Patel V, Borysenko M, Kumar MSA, Millard WJ. 1985. Effects of acute and subchronic delta-9-tetrahydrocannabinol administration on the plasma catecholamine, beta-endorphin, and corticosterone levels and splenic natural killer cell activity in rats. Proc. Society for Experimental Biology and Medicine 180:400—404. Pepe S, Ruggiero A, Tortora G, Ciaardiello F, Garbi C, Yokozaki H, Cho-Chung YS, Clair T, Skalhegg BS, Bianco AR. 1994. Flow cytometric detection of the RI alpha subunit of type-I cAMP-dependent protein kinase in human cells. Cytometry 15:73—79. Pert CB, Snyder SH. 1973. Opiate receptor: Demonstration in nervous tissue. Science 179:1011—1014. Pertwee RG. 1997b. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology and Therapeutics 74:129—180. Pertwee RG, Stevenson LA, Griffin G. 1993. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide [published erratum appears in British Journal of Pharmacology, 1994, 111(3):968]. British Journal of Pharmacology 110:1483—1490. Pertwee RG, Wickens AP. 1991. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 30:237—244. Pross SH, Nakano Y, Widen R, McHugh S, Newton C, Klein TW, Friedman H. 1992. Differing effects of delta-9-tetrahydrocannabinol (THC) on murine spleen cell populations dependent upon stimulators. International Journal of Immunopharmacology 14:1019—1027. Razdan RK. 1986. Structure-activity relationships in cannabinoids. Pharmacology Review 38:75—149. Rhee MH, Vogel Z, Barg J, Bayewitch M, Levy R, Hanus L, Breuer A, Mechoulam R. 1997. Cannabinol derivatives: Binding to cannabinoid receptors and inhibition of adenyl-cyclase. Journal of Medicinal Chemistry 40:3228—3233. Richardson JD, Aanonsen L, Hargreaves KM. 1998. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. Journal of Neuroscience 18:451—457. Richardson JD, Kilo S, Hargreaves KM. 1998. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75:111—119. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC, Le Fur G. 1994. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters 350:240—244. Rinaldi-Carmona M, Barth F, Millan J, Defrocq J, Casellas P, Congy C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Breliere J, Le Fur G. 1998. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacology and Experimental Therapeutics 284:644—650. Rodrνguez de Fonseca F, Fernαndez-Ruiz JJ, Murphy LL, Eldridge JC, Steger RW, Bartke A. 1991. Effects of delta-9-tetrahydrocannabinol exposure on adrenal medullary function: Evidence of an acute effect and development of tolerance in chronic treatments. Pharmacology, Biochemistry and Behavior 40:593—598. Rodriguez de Fonseca F, Carrera MRA, Navarro M, Koob G, Weiss F. 1997. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal [see comments Science 1997, 276:1967—1968]. Science 276:2050—2054. Rodriguez de Fonseca F, Gorriti MA, Fernandez-Ruiz JJ, Palomo T, Ramos JA. 1994. Down-regulation of rat brain cannabinoid binding sites after chronic delta-9-tetrahydrocannabinol treatment. Pharmacology, Biochemistry and Behavior 47:33—40. Romero J, Garciα L, Fernαndez-Ruiz JJ, Cebeira M, Ramos JA. 1995. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta-9-tetrahydrocannabinol. Pharmacology, Biochemistry and Behavior 51:731—737. Romero J, Garcia-Palomero E, Castro JG, Garcia-Gil L, Ramos JA, Fernandez-Ruiz JJ. 1997. Effects of chronic exposure to delta-9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Molecular Brain Research 46:100—108. Russell DH. 1978. Type I cyclic AMP-dependent protein kinase as a positive effector of growth. Advances in Cyclic Nucleotide Research 9:493—506. Sanudo-Pena MC, Tsou K, Delay ER, Hohmann AG, Force M, Walker JM. 1997. Endogenous cannabinoids as an aversive or counter-rewarding system in the rat. Neuroscience Letters 223:125—128. Sanudo-Pena MC, Walker JM. 1997. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. Journal of Neurophysiology 77:1635—1638. Schatz AR, Koh WS, Kaminski NE. 1993. Delta-9-tetrahydrocannabinol selectively inhibits T-cell dependent humoral immune responses through direct inhibition of accessory T-cell function. Immunopharmacology 26:129—137. Schlicker E, Timm J, Zenter J, Goethert M. 1997. Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. Naunyn-Schmiedeberg's Archives of Pharmacology 356:583—589. Shen M, Piser TM, Seybold VS, Thayer SA. 1996. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. Journal of Neuroscience 16:4322—4334. Shivers SC, Newton C, Friedman H, Klein TW. 1994. Delta 9-tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human monocyte/macrophage cell lines. Life Sciences 54:1281—1289. Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T. 1997. Cytokine production in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. Journal of Neuroimmunology 72:169—177. Sim LJ, Hampson RE, Deadwyler SA, Childers SR. 1996. Effects of chronic treatment with delta-9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPyS autoradiography in rat brain. Journal of Neuroscience 16:8057—8066. Sim LJ, Xiao R, Selley DE, Childers SR. 1996. Differences in G-protein activation by mu- and delta-opioid, and cannabinoid, receptors in rat striatum. European Journal of Pharmacology 307:97—105. Simon EJ. 1973. In search of the opiate receptor. American Journal of Medical Sciences 266:160—168. Skaper SD, Buriani A, Dal Toso R, Petrelli L, Romanello S, Facci L, Leon A. 1996. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. National Academy of Sciences, USA 93:3984—3989. Smith JW, Steiner AL, Newberry WM, Parker CW. 1971. Cyclic adenosine 3',5'-monophosphate in human lymphocytes: Alteration after phytohemagglutinin. Journal of Clinical Investigation 50:432—441. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. 1994. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacology and Experimental Therapeutics 270:219—227. Smith PB, Welch SP, Martin BR. 1994. Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice. J. Pharmacology and Experimental Therapeutics 268: 1381—1387. Sofia RD, Nalepa SD, Harakal JJ, Vassar HB. 1973. Anti-edema and analgesic properties of delta-9-tetrahydrocannabinol (THC). Journal of Pharmacology and Experimental Therapeutics 186:646—655. Specter S, Lancz G, Hazelden J. 1990. Marijuana and immunity: Tetrahydrocannabinol mediated inhibition of lymphocyte blastogenesis. International Journal of Immunophar-macology 12:261—267. Stefano G, Salzet B, Salzet M. 1997. Identification and characterization of the leech CNS cannabinoid receptor: Coupling to nitric oxide release. Brain Research 753:219—224. Stella N, Schweitzer P, Piomelli D. 1997. A second endogenous cannabinoid that modulates long term potentiation. Nature 388:773—778. Strangman NM, Patrick SL, Hohmann AG, Tsou K, Walker JM. 1998. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Research 813:323—328. Sulcova E, Mechoulam R, Fride E. 1998. Biphasic effects of anandamide. Pharmacology, Biochemistry and Behavior 59:347—352. Szabo B, Dorner L, Pfreundtner C, Norenberg W, Starke K. 1998. Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. Neuroscience 85:395—403. Tanda G, Pontieri FE, Di Chiara G. 1997. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common ΅1 opioid receptor mechanism. Science 276:2048—2049. Terenius L. 1973. Characteristics of the "receptor" for narcotic analgesics in synaptic plasma membrane fraction from rat brain. Acta Pharmacologica Et Toxicologica 33:377—384. Terranova JP, Michaud JC, Le Fur G, Soubriι P. 1995. Inhibition of long-term potentiation in rat hippocampal slice by anandamide and WIN55212-2: Reversal by SR141716 A, a selective antagonist of CB1 cannabinoid receptors. Naunyn-Schmiedeberg's Archives of Pharmacology 352:576—579. Titishov N, Mechoulam R, Zimmerman AM. 1989. Stereospecific effects of (—) and (+)-7-hydroxy-delta-6- tetrahydrocannabinol-dimethylheptyl on the immune system of mice. Pharmacology 39:337—349. Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. 1998. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83:393—411. Tsou K, Patrick SL, Walker JM. 1995. Physical withdrawal in rats tolerant to delta-9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. European Journal of Pharmacology 280:R13—R15. Watson PF, Krupinski J, Kempinski A, Frankenfield C. 1994. Molecular cloning and characterization of the type VII isoform of mammalian adenylyl cyclase expressed widely in mouse tissues and in S49 mouse lymphoma cells. Journal of Biological Chemistry 269:28893—28898. Watzl B, Scuder P, Watson RR. 1991. Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro. International Journal of Immunopharmology 13:1091—1097. Weidenfeld J, Feldman S, Mechoulam R. 1994. Effect of the brain constituent an-andamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinology 59:110—112. Welch SP. 1993. Blockade of cannabinoid-induced antinociception by norbinal-torphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J. Pharmacology and Experimental Therapeutics 265:633—640. Welch SP, Thomas C, Patrick GS. 1995. Modulation of cannabinoid-induced anti-nociception after intracerebroventricular versus intrathecal administration to mice: Possible mechanisms for interaction with morphine. Journal of Clinical and Experimental Therapeutics 272:310—321. Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T. 1994. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharma-cology 28:209—214. Wirth PW, Watson ES, ElSohly M, Turner CE, Murphy JC. 1980. Anti-inflammatory properties of cannabichromene. Life Sciences 26:1991—1995. Yaksh TL. 1981. The antinociceptive effects of intrathecally administered levon-antradol and desacetyl-levonantradol in the rat. Journal of Clinical Pharmacology 21:334S—340S. Yoshida H, Usami N, Ohishi Y, Watanabe K, Yamamoto I, Yoshimura H. 1995. Synthesis and pharmacological effects in mice of halogenated cannabinol derivatives. Chemical and Pharmaceutical Bulletin 42:335—337. Zhu W, Newton C, Daaka Y, Friedman H, Klein TW. 1994. Delta 9-tetrahydrocannabinol enhances the secretion of interleukin 1 from endotoxin-stimulated macrophages. J. Pharmacology and Experimental Therapeutics 270:1334—1339. Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG. 1982. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 76:245—250. Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, Burstein SH. 1998. Dimethylheptyl-THC-11 oic acid: A non-psychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis and Rheumatism 41:163—170.

    M. Navarro, etal 2001, Functional Interaction between Opioid and Cannabinoid Receptors In Self Drug Administration. Journal of Neuroscience, 21(14):5344­5350 Basavarajappa BS, Hungund BL (1999) Down-regulation of cannabinoid receptor agonist-stimulated [35S]-GTP S binding in synaptic plasma membrane from chronic ethanol-exposed mouse. Brain Res 815:89­97. Chaperon F, Soubrie΄ P, Puech AJ, Thiebot MH (1998) Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 135:324­332. Comings DE, Muhleman D, Gade R, Johnson P, Verde R, Saucier G, MacMurray J (1997) Cannabinoid receptor gene (CNR1): association with iv drug use. Mol Psychiatry 2:161­168. Diana M, Melis M, Muntoni AL, Gessa GL (1998) Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci USA 95:10269­10273. Gallate JE, Saharov T, Mallet PE, McGregor IS (1999) Increased motivation for beer in rats following the administration of a cannabinoid CB1 receptor agonist. European J Pharmacol 370:233­240. Gardner EL, Vorel RS (1998) Cannabinoid transmission and reward related events. Neurobiol Dis 5:502­533. Giuffrida A, Parsons LH, Kerr TM, Rodri΄guez de Fonseca F, Navarro M, Piomelli D (1999) Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci 2:358­363. Hine B, Friedman E, Torrelio M, Gershon S (1975) Morphine-dependent rats: blockade of precipitated abstinence by tetrahydrocannabinol. Science 187:443­445. Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, Maldonado R (1998) Behavioural and biochemical evidence for signs of abstinence in mice treated chronically with delta-9-tetrahydrocannabinol. Br J Pharmacol 125:1567­1577. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283:401­404. Mailleux P, Vanderhaeghen JJ (1994) Delta-9-tetrahydrocannabinol regulates substance P and enkephalin mRNAs levels in caudate putamen. European J Pharmacol 267:R1­R3. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA (1999) Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20:287­294. Martin TJ, Kim SA, Cannon DG, Sizemore GM, Bian D, Porreca F, Smith SE (2000) Antagonism of delta(2)-opioid receptors by naltrindole-5-isothiocyanate attenuates heroin self-administration but not antinociception in rats. J Pharmacol Exp Ther 294:975­982. Mascia MS, Obinu MC, Ledent C, Parmentier M, Bohme GA, Imperato A, Fratta W (1999) Lack of morphine-induced dopamine release in the nucleus accumbens of Cannabinoid CB#--receptor knockout mice. European J Pharmacol 383:R1­R2. Mason Jr DJ, Lowe J, Welch SP (1999) A diminution of delta-9-tetrahydrocannabinol modulation of dynorphin A(1­17) in conjunction with tolerance development. European J Pharmacol 381:105­111. Rodri΄guez de Fonseca F, Roberts AJ, Bilbao A, Koob GF, Navarro M (1999) Cannabinoid receptor antagonist SR141716a decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers. Acta Pharmacol Sin 20:1109­1114. Rubino T, Tizzoni L, Vigano D, Massi P, Parolaro D (1997) Modulation of rat brain cannabinoid receptors after chronic morphine treatment. NeuroReport 8:3219­3223. Welch SP, Stevens DL (1992) Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 262:10­16.

    Freedom To Exhale, Cannabinoids In Pain Managementx Leslie Iversen, 2001 Few well controlled trials of cannabis exist for systematic review Campbell FA, Tramθr MR, Carroll D, Reynolds DJM, Moore RA, McQuay HJ. 2001 Are cannabinoids an effective and safe option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 13-16 Iversen LL. 2000 The science of marijuana. Oxford: Oxford University Press, 2000. House of Lords Select Committee on Science and Technology. 2001 Second report on therapeutic uses of cannabis. London: Stationery Office, 2001. Pertwee RG. 2001 Cannabinoid receptors and pain. Prog Neurobiol 2001; 63: 569-611. Denis J Petro 2001 Spasticity is not the same as pain 2001 Campbell FA, Tramθr MR, Carroll D, Reynolds DJM, Moore RA, McQuay HJ. Are cannabinoids an effective and safe option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 13-16. Petro DJ, Ellenberger Jr C. 1981 Treatment of human spasticity with delta-9-tetrahydrocannabinol. J Clin Pharmacol 1981; 21(suppl 8-9): S413-S416. Meinck HM, Schonle PW, Conrad B. 1989 Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 1989; 236: 120-122. Ungerleider JT, Andyrsiak T, Fairbanks L, Ellison GW, Myers LW. 1987 Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse 1987; 7: 39-50. Martyn CN, Illis LS, Thom J. 1995 Nabilone in the treatment of multiple sclerosis. Lancet 1995; 345: 579. Franjo Grotenhermen 2001 Cannabinoid receptor agonists will soon find their place in modern medicine 2001 Campbell FA, Tramθr MR, Carroll D, Reynolds DJM, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 13-16. Tramθr MR, Carroll D, Campbell FA, Reynolds DJM, Moore RA, McQuay HJ. 2001 Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323: 16-21/ Grotenhermen F. 1999 Cannabis in der Schmerztherapie-ein neues Adjuvans? [Cannabis in pain therapya new adjuvant?] Forschung und Praxis, Wissenschaftsjournal der Δrztezeitung 1999; 276: 22-26. Kalso E. 2001 Cannabinoids for pain and nausea. BMJ 2001; 323: 2-3. Gonzalez-Rosales F, Walsh D. 1997 Intractable nausea and vomiting due to gastrointestinal mucosal metastases relieved by tetrahydrocannabinol (dronabinol). J Pain Symptom Manage 1997; 14: 311-314.

    Fiona A Campbell, Martin R Tramθr, Dawn Carroll, D John M Reynolds, R Andrew Moore, and Henry J McQuay, 2001 Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001 323: 13.

    Krumm BA, 1990's Cannabis (Medical) Research Library Articles On Cannabis Receptors PDF Article Archives 1990's

    Chaperon F, Thiebot MH, 1999 Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 1999; 13(3):243-81

    Pertwee RG, 2001 Cannabinoid Receptor Ligands Tocris Cookson Inc., Ellisville Missouri 63021 USA References: 1. Matsuda et al (1990) Nature 346 561. 2. Munro et al (1993) Nature 365 61. 3. Matsuda (1997) Crit.Revs.Neurobiol. 11 143. 4. Buckley et al (2000) Eur.J.Pharmacol. 396 141. 5. Ledent et al (1999) Science 283 401. 6. Zimmer et al (1999) Proc.Natl.Acad.Sci.USA 96 5780. 7. Chakrabarti et al (1995) DNA Sequence 5 385. 8. Gιrard et al (1990) Nucleic Acids Res. 18 7142. 9. Shire et al (1996) Biochim.Biophys.Acta 1307 132. 10. Rinaldi-Carmona et al (1996) J.Pharmacol.Exp.Ther. 278 871. 11. Shire et al (1995) J.Biol.Chem. 270 3726. 12. Pertwee (1997) Pharmacol.Ther. 74 129. 13. Ong and Mackie (1999) Neuroscience 92 1177. 14. Pertwee (2001) Progr.Neurobiol. 63 569. 15. Galiθgue et al (1995) Eur.J.Biochem. 232 54. 16. Molina-Holgado et al (1999) Biodrugs 12 317. 17. Berdyshev (2000) Chem.Phys.Lipids 108 169. 18. Pertwee (1998) In Cannabis: The Genus Cannabis. Ed. Brown, D.T., p 125, Harwood Academic Publishers, Amsterdam. 19. Howlett and Mukhopadhyay (2000) Chem.Phys.Lipids 108 53. 20. Mu et al (1999) J.Pharmacol.Exp.Ther. 291 893. 21. Mu et al (2000) Pflόgers Arch.Eur.J.Physiol. 439 541. 22. Ho et al (1999) Receptors & Channels 6 363. 23. McAllister et al (1999) J.Pharmacol.Exp.Ther. 291 618. 24. Schweitzer (2000) J.Neurosci. 20 51. 25. Glass and Felder (1997) J.Neurosci. 17 5327. 25. 26. Calandra et al (1999) Eur.J.Pharmacol. 374 445. 27. Hampson et al (2000) J.Neurophysiol. 84 2356. 28. Gebremedhin et al (1999) Am.J.Physiol. 276 H2085. 29. Netzeband et al (1999) J.Neurosci. 19 8765. 30. Devane et al (1992) Science 258 1946. 31. Di Marzo et al (1998) TiNS 21 521. 32. Mechoulam et al (1998) Eur.J.Pharmacol. 359 1. 33. Sugiura and Waku (2000) Chem.Phys.Lipids 108 89. 34. Di Marzo (1999) Life Sci. 65 645. 35. Piomelli et al (1999) Proc.Natl.Acad.Sci.USA 96 5802. 36. Maccarrone et al (1998) J.Biol.Chem. 273 32332. 37. Hillard and Jarrahian (2000) Chem.Phys.Lipids 108 123. 38. Giuffrida et al (1999) Nature Neurosci. 2 358. 39. Ueda et al (2000) Chem.Phys.Lipids 108 107. 40. Khanolkar and Makriyannis (1999) Life Sci. 65 607. 41. Thomas et al (1997) J.Neurosci.Res. 50 1047. 42. Tsou et al (1998) Neurosci.Lett. 254 137. 43. Ueda and Yamamoto (2000) Prostaglandins & Other Lipid Mediators 61 19. 44. Cravatt et al (1996) Nature 384 83. 45. Pertwee (1999) Curr.Med.Chem. 6 635. 46. Ben-Shabat et al (1998) Eur.J.Pharmacol. 353 23. 47. Pertwee (2000) Expert Opin.Invest.Drugs 9 1553. 48. Johnson and Melvin (1986) In Cannabinoids as Therapeutic Agents. Ed. Mechoulam, R., p 121, CRC Press, Boca Raton. 49. Martin et al (1991) Pharmacol.Biochem.Behav. 40 471. 50. Pacheco et al (1991) J.Pharmacol.Exp.Ther. 257 170. 51. Abadji et al (1994) J.Med.Chem. 37 1889. 52. Reggio and Traore (2000) Chem.Phys.Lipids 108 15. 53. Khanolkar et al (2000) Chem.Phys.Lipids 108 37. 54. Bayewitch et al (1996) J.Biol.Chem. 271 9902. 55. Pertwee et al (2000) Br.J.Pharmacol. 129 1577. 56. Hillard et al (1999) J.Pharmacol.Exp.Ther. 289 1427. 57. Jarrahian et al (2000) J.Neurochem. 74 2597. 58. Hanus et al (1999) Proc.Natl.Acad.Sci.USA 96 14228. 59. Ross et al (1999) Br.J.Pharmacol. 126 665. 60. Rinaldi-Carmona et al (1994) FEBS Lett. 350 240. 61. Deutsch et al (1997) Biochem.Pharmacol. 53 255. 62. Lan et al (1999) AAPS Pharmsci. 1 U13, article 4, http://www.pharmsci.org/. 63. Bouaboula et al (1997) J.Biol.Chem. 272 22330. 64. Coutts et al (2000) Br.J.Pharmacol. 129 645. 65. MacLennan et al (1998) Br.J.Pharmacol. 124 619. 66. Gatley et al (1998) J.Neurochem. 70 417. 67. Al-Hayani and Davies (2000) Br.J.Pharmacol. 131 663. 68. Izzo et al (2000) Br.J.Pharmacol. 129 984. 69. Gifford et al (1997) Neurosci.Lett. 238 84. 70. Cosenza et al (2000) Synapse 38 477. 71. Ross et al (2001) Br.J.Pharmacol. 132 631. 72. Zygmunt et al (1999) Nature 400 452. 73. Adams et al (1998) J.Pharmacol.Exp.Ther. 284 1209. 74. Di Marzo et al (2000) Eur.J.Pharmacol. 406 363. 75. Smith et al (1998) Pharmacol.Biochem.Behav. 60 183. 76. Smart et al (2000) Br.J.Pharmacol. 129 227. 77. Smart and Jerman (2000) TiPS 21 134. 78. Jerman et al (2000) Br.J.Pharmacol. (Proc. Suppl.) 129 73P. 79. Melck et al (1999) Biochem.Biophys.Res.Comm. 262 275. 80. Zygmunt et al (2000) Eur.J.Pharmacol. 396 39. 81. Rinaldi-Carmona et al (1998) J.Pharmacol.Exp.Ther. 284 644. 82. Ross et al (1999) Br.J.Pharmacol. 128 735. 83. Hosohata et al (1997) Life Sci. 61 PL115. 84. Hosohata et al (1997) Eur.J.Pharmacol. 321 R1. 85. Pertwee et al (1996) Br.J.Pharmacol. 118 2199. 86. Landsman et al (1998) Life Sci. 62 PL109. 87. Ross et al (1998) Br.J.Pharmacol. 125 1345. 88. Gatley et al (1997) Life Sci. 61 PL191. 89. Lan et al (1996) J.Labelled Comp.Radiopharm. 38 875. 90. Barth (1998) Exp.Opin.Ther.Patents 8 301. 91. Deutsch et al (1997) Biochem.Biophys.Res.Comm. 231 217. 92. Gifford et al (1999) Eur.J.Pharmacol. 383 9. 93. Cervone et al (1999) Proc.Soc.Neurosci. 25 2077. 94. Baker et al (2000) Nature 404 84. 95. Baker et al (2001) FASEB J. 15 300. 96. Fernando and Pertwee (1997) Br.J.Pharmacol. 121 1716. 97. Martin et al (2000) J.Pharmacol.Exp.Ther. 294 1209. 98. Compton and Martin (1997) J.Pharmacol.Exp.Ther. 283 1138. 99. Edgemond et al (1998) J.Pharmacol.Exp.Ther. 286 184. 100. Beltramo et al (1997) FEBS Lett. 403 263. 101. Di Marzo and Deutsch (1998) Neurobiol.Dis. 5 386. 102. Koutek et al (1994) J.Biol.Chem. 269 22937. 103. Boger et al (2000) Proc.Natl.Acad.Sci.USA 97 5044. 104. Desarnaud et al (1995) J.Biol.Chem. 270 6030. 105. Maurelli et al (1995) FEBS Lett. 377 82. 106. Mechoulam et al (1997) Nature 389 25. 107. Gallily et al (2000) Eur.J.Pharmacol. 406 R5. 108. Hillard and Campbell (1997) J.Lipid Res. 38 2383. 109. Pertwee (1998) Biochem.Soc.Transact. 26 267. 110. Bisogno et al (2000) Biochem.J. 351 817. 111. Beltramo et al (1997) Science 277 1094. 112. Gonzαlez et al (1999) Life Sci. 65 327. 113. Beltramo et al (2000) J.Neurosci. 20 3401. 114. Giuffrida et al (2000) Eur.J.Pharmacol. 408 161. 115. Khanolkar et al (1996) J.Med.Chem. 39 4515. 116. De Petrocellis et al (2000) FEBS Lett. 483 52. 117. Muthian et al (2000) J.Pharmacol.Exp.Ther. 293 289. 118. Calignano et al (1998) Nature 394 277. 119. Lambert et al (1999) Biochim.Biophys.Acta 1440 266. 120. Sheskin et al (1997) J.Med.Chem. 40 659. 121. Showalter et al (1996) J.Pharmacol.Exp.Ther. 278 989. 122. Griffin et al (1997) Eur.J.Pharmacol. 339 53. 123. Jαrai et al (1999) Proc.Natl.Acad.Sci.USA 96 14136. 124. Kunos et al (2000) Chem.Phys.Lipids 108 159. 125. Di Marzo et al (2000) J.Neurochem. 75 2434. 126. Hanus et al (2001) The presence in the brain of a novel CB1-selective endocannabinoid, 2-arachidonoyl glyceryl ether (noladin ether), Proc.Natl.Acad.Sci.USA 98 3662. Graeme Henderson, Sandy McKnight and Alistair Corbett Opiate And Cannabinoid Receptors Poster Table of Cannabinoid Receptor Pharmacology Cannabinoid Receptors (CB1 and CB2) and Fatty Acid Amide Hydrolase (FAAH), Antibodies Alpha Diagnostic International, Inc. 5415 Lost Lane, San Antonio, TX 78238 USA


    VITAMIN E RECEPTORS: Csaba G, Karabelyos CS. 2000 Influence of a single treatment with vitamin E or K (hormonal imprinting) of neonatal rats on the sexual behavior of adults. Acta Physiol Hung. 2000;87(1):25-30. PMID: 11032045 [PubMed - indexed for MEDLINE] Donchenko GV, Parkhomenko IuM, Parkhomets PK, Chernukhina LA, Petrova GV. 1992 Theoretical and practical aspects of studying specific proteins-- acceptors of vitamins and coenzymes Vopr Med Khim. 1992 Jul-Aug;38(4):6-10. Review. Russian. PMID: 1334297 [PubMed - indexed for MEDLINE] Gonzalez MJ. 1990 Serum concentrations and cellular uptake of vitamin E. Med Hypotheses. 1990 Jun;32(2):107-10. Review. PMID: 2165554 [PubMed - indexed for MEDLINE] Kitabchi AE, Wimalasena J. 1982 Demonstration of specific binding sites for 3H-RRR-alpha-tocopherol on human erythrocytes. Ann N Y Acad Sci. 1982;393:300-14. PMID: 6293366 [PubMed - indexed for MEDLINE] Murphy DJ, Mavis RD. 1981 Membrane transfer of alpha-tocopherol. Influence of soluble alpha-tocopherol-binding factors from the liver, lung, heart, and brain of the rat. J Biol Chem. 1981 Oct 25;256(20):10464-8. PMID: 6270112 [PubMed - indexed for MEDLINE] Kitabchi AE, Wimalasena J, Barker J. 1980 Specific receptor sites for alpha-tocopherol in purified isolated adrenocortical cell membrane. Biochem Biophys Res Commun. 1980 Oct 31;96(4):1739-46. PMID: 6255955 [PubMed - indexed for MEDLINE] Kitabchi AE, Wimalasena J. 1982 Specific binding sites for D-alpha-tocopherol on human erythrocytes. Biochim Biophys Acta. 1982 Jan 22;684(2):200-6. PMID: 7055562 [PubMed - indexed for MEDLINE] Wimalasena J, Davis M, Kitabchi AE. 1982 Characterization and solubilization of the specific binding sites for d-alpha-tocopherol from human erythrocyte membranes. Biochem Pharmacol. 1982 Nov 1;31(21):3455-61. PMID: 7150365 [PubMed - indexed for MEDLINE] Bellizzi MC, Dutta-Roy AK, James WP. 1997 High D-glucose does not affect binding of alpha-tocopherol to human erythrocytes. Mol Cell Biochem. 1997 May;170(1-2):187-93. PMID: 9144334 [PubMed - indexed for MEDLINE] Kitabchi AE, Wimalasena J, Barker J. 1980 Specific receptor sites for alpha-tocopherol in purified isolated adrenocortical cell membrane. Biochem Biophys Res Commun. 1980 Oct 31;96(4):1739-46. PMID: 6255955 [PubMed - indexed for MEDLINE] Murphy DJ, Mavis RD. 1981 Membrane transfer of alpha-tocopherol. Influence of soluble alpha-tocopherol-binding factors from the liver, lung, heart, and brain of the rat. J Biol Chem. 1981 Oct 25;256(20):10464-8. PMID: 6270112 [PubMed - indexed for MEDLINE] Clement M, Dinh L, Bourre JM. 1995 Uptake of dietary RRR-alpha- and RRR-gamma-tocopherol by nervous tissues, liver and muscle in vitamin-E-deficient rats. Biochim Biophys Acta. 1995 May 17;1256(2):175-80. PMID: 7766695 [PubMed - indexed for MEDLINE] Dutta-Roy AK. 1999 Molecular mechanism of cellular uptake and intracellular translocation of alpha-tocopherol: role of tocopherol-binding proteins. Food Chem Toxicol. 1999 Sep-Oct;37(9-10):967-71. PMID: 10541452 [PubMed - indexed for MEDLINE]

    Notes 1 The field of neuroscience has grown substantially since the publication of the 1982 IOM report. The number of members in the Society for Neuroscience provides a rough measure of the growth in research and knowledge about the brain: as of the middle of 1998, there were over 27,000 members, more than triple the number in 1982. 2 Affinity is a measure of how avidly a compound binds to a receptor. The higher the affinity of a compound, the higher its potency; that is, lower doses are needed to produce its effects. 3 Eicosanoids all contain a chain of 20 carbon atoms and are named after eikosi, the Greek word for 20. 4 Neurons are often defined by the primary neurotransmitter released at their terminals. Thus, cholinergic neurons release acetylcholine, noradrenergic neurons release noradrenalin (also known as norepinephrine), and glutamergic neurons release glutamate. 5 After a gene is transcribed, it is often spliced and modified into mRNA, or message RNA. The CB-2 mRNA is the gene "message" that moves from the cell nucleus into the cytoplasm where it will be translated into the receptor protein. 6 Mitogens are substances that stimulate cell division (mitosis) and cell transformation. 7 While 3 mg/kg would be a high dose for humans (see Table 3.1), in rodents, it is a low dose for immunological effects and a moderate dose for behavioral effects. 8 In vitro studies are those in which animal cells or tissue are removed and studied outside the animal; in vivo studies are those in which experiments are conducted in the whole animal. 9 Antinociception: inhibition of the perception of pain.
    Medical Marijuana Doctors Vitamin M

Pubmed Literature Search